Veeva Systems (VEEV) Stock Forecast & Price Target

$313.01 +15.66 (+5.27%)

Closing price 10/15/2026 03:59 PM Eastern

Extended Trading

$314.36 +1.35 (+0.43%)

As of 10/15/2026 08:00 PM Eastern

Compare

Veeva Systems - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 28 Analyst Ratings

Sell
1

Hold
8

Buy
19

Based on 28 Wall Street analysts who have issued ratings for Veeva Systems in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 28 analysts, 1 has given a sell rating, 8 have given a hold rating, and 19 have given a buy rating for VEEV.

Consensus Price Target

$285.92
-8.65% Downside

According to the 28 analysts' twelve-month price targets for Veeva Systems, the average price target is $285.92. The highest price target for VEEV is $340.00, while the lowest price target for VEEV is $165.00. The average price target represents a forecasted downside of -8.65% from the current price of $313.01.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for VEEV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Veeva Systems and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VEEV Analyst Ratings Over Time

Type	Current Forecast 10/16/25 to 10/16/26	1 Month Ago 9/16/25 to 9/16/26	3 Months Ago 7/18/25 to 7/18/26	1 Year Ago 10/16/24 to 10/16/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	19 Buy rating(s)	19 Buy rating(s)	18 Buy rating(s)	16 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	8 Hold rating(s)	7 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$285.92	$284.88	$247.74	$307.58
Forecasted Upside	-8.65% Downside	7.55% Upside	26.64% Upside	5.08% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

VEEV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VEEV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Veeva Systems Stock vs. The Competition

Type	Veeva Systems	Healthcare Companies	Broader Market
Consensus Rating Score	2.64	2.32	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	-8.65% Downside	1,138.76% Upside	17.80% Upside
News Sentiment Rating	Positive News See Recent VEEV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/15/2026	Oppenheimer 3 of 5 stars	Ken Wong 1 of 5 stars	Reiterated Rating	Outperform	$325.00	+9.36%
10/8/2026	Weiss Ratings 3 of 5 stars		Upgrade	Hold (C) ➝ Hold (C+)
9/8/2026	Wells Fargo & Company 3 of 5 stars	Stan Berenshteyn 2 of 5 stars	Reiterated Rating	Overweight	$330.00	+20.43%
8/28/2026	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Tyler Radke Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Neutral	$190.00 ➝ $273.00	-3.63%
8/27/2026	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Billy Fitzsimmons Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$295.00 ➝ $320.00	+12.09%
8/27/2026	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	David Grossman Subscribe to MarketBeat All Access to unlock analyst rankings	Set Target		$300.00	+3.88%
8/27/2026	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Ryan MacDonald Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$270.00 ➝ $310.00	+26.68%
8/27/2026	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Buy	$295.00	+20.55%
8/27/2026	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Steven Valiquette Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Outperform	$270.00 ➝ $280.00	-1.12%
8/27/2026	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Joe Vruwink Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Outperform	$260.00 ➝ $300.00	+5.23%
Get the Latest News and Ratings for VEEV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Veeva Systems and its competitors with MarketBeat's FREE daily newsletter.
8/27/2026	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Sean Dodge Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Market Perform	$175.00 ➝ $270.00	-5.29%
8/27/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	David Hynes Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Hold	$220.00 ➝ $260.00	-9.29%
8/27/2026	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Saket Kalia Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$275.00 ➝ $315.00	+11.03%
8/27/2026	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Karl Keirstead Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Neutral	$190.00 ➝ $290.00	+0.50%
8/27/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Rishi Jaluria Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Outperform	$275.00 ➝ $325.00	+12.29%
8/27/2026	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Tamjid Chowdhury Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$276.00 ➝ $310.00	+6.38%
8/27/2026	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Craig Hettenbach Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Equal Weight	$215.00 ➝ $275.00	-2.12%
8/27/2026	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Jailendra Singh Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$262.00 ➝ $305.00	+24.63%
8/24/2026	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Charles Rhyee Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$235.00 ➝ $283.00	+13.81%
6/4/2026	BNP Paribas Exane Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Outperform	$285.00	+59.54%
6/4/2026	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Outperform	$185.00	+3.53%
6/4/2026	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Outperform	$225.00	+25.92%
6/4/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Gabriela Borges Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Sell	$190.00 ➝ $165.00	-7.23%
6/4/2026	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	David Larsen Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy	$340.00	+90.27%
5/14/2026	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings		Downgrade	Strong-Buy ➝ Hold
3/10/2026	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Outperform
2/20/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Alexei Gogolev Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Overweight	$330.00 ➝ $296.00	+63.66%
12/12/2025	KeyCorp Subscribe to MarketBeat All Access to unlock brokerage rankings	Scott Schoenhaus Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Overweight ➝ Sector Weight
3/6/2025	Scotiabank Subscribe to MarketBeat All Access to unlock brokerage rankings	A. Verkhovski Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Sector Perform	$240.00 ➝ $245.00	+3.61%
3/6/2025	Stephens Subscribe to MarketBeat All Access to unlock brokerage rankings	Jeff Garro Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Overweight	$280.00 ➝ $280.00	+19.63%
12/6/2024	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Neutral	$280.00 ➝ $290.00	+13.44%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:44 AM ET.

Should I Buy Veeva Systems Stock? VEEV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 15, 2026. Please send any questions or comments about these Veeva Systems pros and cons to contact@marketbeat.com.

Veeva Systems
Bull Case

Here are some ways that investors could benefit from investing in Veeva Systems Inc.:

Veeva Systems Inc. recently expanded its partnership with IQVIA, which selected Veeva's Clinical Trial Management System, electronic Trial Master File, Study Startup, and Site Connect products as enterprise standards across its global research operations. This strategic move deepens Veeva's role in clinical execution workflows and broadens its reach across contract research and biopharma customers, potentially increasing recurring revenue and customer retention.
The company reported strong third-quarter earnings, beating analysts' consensus estimates with $2.35 in earnings per share compared to the expected $2.23. Revenue also exceeded expectations at $927.96 million, up 17.6% year-over-year, demonstrating robust demand for its cloud-based software solutions in the life sciences industry.
Veeva Systems Inc. has set aggressive guidance for fiscal year 2027, projecting earnings per share of $9.21 and revenue of $3.7 billion. This guidance significantly exceeds the consensus estimates of $8.58 for EPS and $3.6 billion for revenue, indicating management's confidence in continued growth and operational efficiency.
The stock is currently trading at $313.01, near its 52-week high of $315.02, reflecting strong investor sentiment and technical momentum. This price level suggests that the market is valuing the company's growth trajectory and market position highly, with institutional investors showing increased interest in the stock.
Veeva's Veeva Basics suite is gaining traction with more than 175 emerging biotechnology companies, supporting the company's strategy of building early relationships that may develop into larger, long-term customers as these firms advance their drug pipelines. This broadening adoption among early-stage biotechs could unlock long-term revenue opportunities.

Veeva Systems
Bear Case

Investors should be bearish about investing in Veeva Systems Inc. for these reasons:

The company's price-to-earnings ratio stands at 48.04, which is relatively high compared to many other software companies. This valuation may leave little room for error if growth slows or if the company fails to meet its aggressive earnings guidance, potentially leading to a significant stock price correction.
Insider selling has been notable, with executives such as Daniel J. Rizzo and Thomas D. Schwenger selling significant portions of their holdings in recent months. For example, Rizzo sold 4,841 shares in October, and Schwenger sold 10,000 shares in August, which could signal a lack of confidence in the stock's near-term upside or simply reflect personal financial planning.
Some institutional investors have reduced their stakes in Veeva Systems Inc. For instance, Curated Wealth Partners LLC cut its stake by 45.6% during the third quarter, and Seilern Investment Management Ltd sold 138,217 shares. These moves could indicate that some large investors are taking profits or reassessing their positions in the stock.
The company's research and development spending is expected to decelerate, as noted by Oppenheimer, which could impact its ability to innovate and maintain its competitive edge in the rapidly evolving life sciences technology sector. This deceleration may be a concern for investors who prioritize ongoing innovation and product development.
Veeva Systems Inc. does not pay a dividend, with a dividend yield of 0.00%. This may be a drawback for income-focused investors who prefer stocks that provide regular cash flows, especially in a market where dividend-paying stocks are often favored for their stability and income potential.

VEEV Forecast - Frequently Asked Questions

According to the research reports of 28 Wall Street equities research analysts, the average twelve-month stock price forecast for Veeva Systems is $285.92, with a high forecast of $340.00 and a low forecast of $165.00.

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veeva Systems in the last twelve months. There is currently 1 sell rating, 8 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VEEV shares.

According to analysts, Veeva Systems's stock has a predicted downside of -8.65% based on their 12-month stock forecasts.

Over the previous 90 days, Veeva Systems's stock had 3 upgrades by analysts.

Veeva Systems has been rated by research analysts at Barclays, BMO Capital Markets, Canaccord Genuity Group, Citigroup, Guggenheim, Jefferies Financial Group, Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, Robert W. Baird, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Veeva Systems more than other "healthcare" companies. The consensus rating for Veeva Systems is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how VEEV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Veeva Systems Recommendations

MarketBeat monitors more than a dozen sources for Veeva Systems analyst ratings, with the most recent rating issued on 10/15/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veeva Systems (VEEV) Stock Forecast & Price Target